CUC Inc.

CUC Inc.

TTSE:9158
578.00
JPY
-15.00
(-2.53%)
75.11EPS
9.77P/E
23.10BMarket Cap
Feb 02Next Earn
CUC Inc.
TSE:9158
(Tokyo Stock Exchange)

Recent

price

578.00

P/E

ratio

9.77

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
JPY
- -
583.13
1,692.06
1,655.25
1,196.15
1,604.81
1,853.98
1,893.75
Revenue per Share
- -
38.63
129.71
113.91
93.99
106.81
97.35
80.67
Basic EPS, GAAP
- -
57.45
276.37
-151.66
-27.06
-105.21
-31.11
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
118.62
166.24
332.09
410.99
931.8
1,012.37
1,134.32
1,140.22
Book Value per Share
-86.74
-118.59
83.86
147.7
315.67
399.35
486.09
448.95
Tangible Book Value per Share
28
28
21
21
28
29
29
29
Basic Weighted Avg Shares
- -
16,606
35,314
35,210
33,025
47,043
54,353
55,516
Sales/Revenue/Turnover
- -
9.81
10.42
10.46
11.31
11.36
10.64
9.13
Operating Margin (%)
- -
801
1,068
1,221
1,806
3,286
4,896
- -
Depreciation Expense
- -
1,100
2,707
2,423
2,595
3,131
2,854
2,365
Net Income, GAAP
- -
30.34
38.71
33.85
37
41.35
46.32
49.06
Effective Tax Rate (%)
- -
6.62
7.67
6.88
7.86
6.66
5.25
4.26
Profit Margin (%)
-6,029
-6,430
-4,185
-8,558
9,260
7,074
15,292
17,687
Working Capital
1,510
3,743
3,527
4,523
23,560
37,963
45,705
49,030
LT Debt
3,977
5,345
9,679
11,920
28,005
30,286
33,891
33,825
Total Equity
- -
5.04
8.88
8.12
5.26
4.79
3.81
3.1
Return on Invested Capital (%)
- -
5.25
13.37
8.65
6.27
5.42
4.19
3.54
Return on Capital (%)
- -
27.12
38.15
22.9
13.3
10.99
9.07
7.51
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
6,394
6,828
7,663
LT Borrowings
29,565
28,578
32,341
LT Finance Leases
17,219
17,127
16,689
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
24,859
25,534
23,100

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
27,696
30,132
32,333
Cash, Cash Equivalents & STI
13,372
15,897
18,418
Accounts Receivable, Net
13,457
13,090
12,774
Inventories
110
113
99
Total Current Liabilities
13,256
14,840
14,646
Payables & Accruals
- -
- -
- -
ST Debt
6,394
6,828
7,663
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
51.84%
11.9%
Free Cash Flow
- -
52.44%
-70.43%
Net Income, GAAP
- -
30.9%
-8.85%
Sales/Revenue/Turnover
- -
32.83%
15.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
10,597
11,014
12,951
12,481
47,043
2026
12,996
13,295
13,879
14,183
54,353
2027
14,159
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
32.94
35.58
25.96
12.31
106.81
2026
7.1
13.78
28.01
48.47
97.35
2027
-9.59
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Business
CUC Inc. is a Japan-based healthcare services company primarily engaged in medical institution support and home healthcare nursing. Founded in 2014 and headquartered in Minato-Ku, Tokyo, it operates as a subsidiary of M3 Inc. The company offers a comprehensive range of products and services including hospital care management support, dialysis care, hospice operation, home nursing, day services, in-home nursing care support, and in-home clinical trial and monitoring services. It provides management and operational support to medical institutions, running over 106 facilities in Japan and Southeast Asia, alongside more than 37 hospice facilities and 89 in-home nursing stations in Japan. CUC also delivers healthcare consulting services and aims to optimize hospital decision-making and operations while driving revenue growth. In terms of geographic operations, CUC is expanding beyond Japan into the United States and Asia. Recent major changes include CUC's first acquisition in the United States in January 2024, when it acquired Beyond Podiatry, a premier podiatry service platform, marking a significant step in expanding its global presence and healthcare delivery in the U.S. Additionally, in November 2025, CUC signed a Memorandum of Understanding with Dr. Yuji Okuno to form a strategic partnership to expand musculoskeletal embolotherapy treatment in the U.S., planning to open multiple outpatient-based locations and develop training programs for American physicians and nurses. These moves exemplify CUC's strategic shift towards broadening its service offerings and geographic footprint in North America alongside maintaining strong growth in Japan and Asia. As of March 2025, CUC's capital stands at approximately JPY 7.7 billion, and its operations focus heavily on delivering patient-centered healthcare solutions through innovative management and clinical service models. This positioning reinforces CUC's commitment to "Creating Hope through Healthcare" and underscores its evolving role as a multi-regional healthcare solutions provider specializing in medical institution support, home-based care, hospice services, and innovative outpatient treatment expansion.